Stocks of the Hour: PharmAust, Impact Minerals, Peregrine Gold
Stocks of the Hour: PharmAust, Impact Minerals, Peregrine Gold
To register for today's webinar click here.
要註冊今天的網絡研討會，請單擊此處。
PharmAust (ASX:PAA & PAAOA) announced it has received Orphan Drug Designation (ODD) from the United States Food and Drug Administration for monepantel and its treatment of Motor Neurone Disease (MND). PharmAust's application was based on preclinical mechanistic data that demonstrates MPL can induce autophagy in diseased cells, and consideration of the pathology of the disease. Shares are trading 13.51 per cent higher at 21 cents.
PharmAust（澳大利亞證券交易所股票代碼：PAA和PAAOA）宣佈，其莫奈太爾及其運動神經元疾病（MND）治療已獲得美國食品藥品監督管理局頒發的孤兒藥認證（ODD）。PharmAust 的應用基於臨床前機制數據，這些數據表明 MPL 可以誘發患病細胞的自噬，並考慮了該疾病的病理。股價上漲13.51％，至21美分。
Impact Minerals (ASX:IPT) has raised $3 million via a strategic placement to fund the Pre-Feasibility Study at their Hope High Purity Alumina Project. $500,000 of that will be used for exploration activities at the Arkun Project. Shares are trading 9.09 per cent lower at 2 cents.
Impact Minerals（澳大利亞證券交易所股票代碼：IPT）已通過戰略配售籌集了300萬美元，爲其Hope高純氧化鋁項目的預可行性研究提供資金。其中50萬美元將用於Arkun項目的勘探活動。股價下跌9.09％，至2美分。
Peregrine Gold (ASX:PGD) has announced that drilling is commencing at the Tin Can Prospect in WA. Initial drilling is planned to extend the mineralisation down plunge, followed by drilling along strike across the broader Tin Can gold in soil anomaly. Shares are flat at 29 cents.
Peregrine Gold（澳大利亞證券交易所股票代碼：PGD）宣佈，正在西澳大利亞州的錫罐勘探區開始鑽探。最初的鑽探計劃將礦化向下延伸，然後沿着走向鑽探到更廣泛的土壤異常中的錫罐金。股價持平至29美分。
